本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 2022 年第三季度报告 证券代码：688265 证券简称：南模生物 上海南方模式生物科技股份有限公司 2022 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 85,440,761.93 | 25.78 | 215,445,3 ...

Financial Performance - The company reported a half-year revenue of 688 million RMB, representing a year-on-year increase of 15%[1] - The net profit for the first half of 2022 was 120 million RMB, up 10% compared to the same period last year[1] - The company reported a revenue of RMB 100 million for the first half of 2022, representing a 20% increase compared to the same period last year[14] - The company's operating revenue for the first half of 2022 was ¥130,004,584.97, representing a 6.73% increase compared to ¥121,804,164.50 in the same period last year[20] - The net profit attributable to shareholders decreased by 81.64% to ¥4,884,254.73 from ¥26,604,883.26 year-on-year[20] - The company achieved a total R&D investment of 23.41 million yuan, representing a 17.05% increase compared to the previous year's 20.00 million yuan[52] - The company achieved a revenue of approximately 130.00 million, representing a year-on-year growth of 6.73%[69] User Growth and Market Expansion - User data indicates a growth in active users by 25%, reaching a total of 1.5 million users[1] - User data showed an increase in active users by 15%, reaching a total of 1.5 million users by June 30, 2022[14] - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by 2025[1] - The company plans to expand its market presence in Europe and North America, targeting a 10% market share in these regions by the end of 2023[14] - The company provided a future outlook, projecting a revenue growth of 25% for the second half of 2022, driven by new product launches and market expansion[14] Research and Development - The company has allocated 50 million RMB for R&D in the next fiscal year to enhance its product offerings[1] - Investment in R&D increased by 30% year-over-year, focusing on gene editing technologies and genetically modified animal models[14] - The company's R&D expenditure accounted for 18.01% of operating revenue, an increase of 1.59 percentage points compared to 16.42% in the previous year[21] - The company has developed over 14,000 models for gene function research and drug development in various disease areas, including tumors and metabolic diseases[29] - The company has independently developed over 8,000 standardized models and provided more than 6,400 customized models to clients, showcasing its extensive experience in gene-modified animal model development[29] - The company has established a comprehensive R&D system and core technology platform for genetically modified animal models, focusing on CRISPR/Cas and ES cell targeting technologies[43][46] Product Development - New product development includes a cutting-edge biotechnological solution expected to launch in Q4 2022, projected to increase revenue by 30%[1] - A new product line related to immune checkpoint inhibitors is expected to launch in Q4 2022, with projected sales of RMB 50 million in the first year[14] - The company has developed a mouse model with a 3-4 times increase in mature oocyte quantity through its self-developed mouse ovulation induction technology[49] - The company has established a spontaneous obesity and insulin resistance model by knocking out the protein related to pancreatic lipase, which can be used for drug screening[48] Operational Challenges - The company faced significant challenges due to COVID-19, impacting revenue recognition and increasing production costs[22] - The company reported a significant increase in operational costs due to expanded production scale and employee compensation during the pandemic[22] - The ongoing uncertainty of the COVID-19 pandemic continues to pose risks to the company's operations, particularly in logistics and client interactions[90] - The company faced significant revenue impacts due to the COVID-19 pandemic, particularly in the Shanghai area, but has since resumed normal operations[69] Financial Management - The net cash flow from operating activities was -¥33,252,222.31, a decline of 204.79% compared to the previous year[22] - The company recognized government subsidies of CNY 2.67 million during the reporting period, which may impact future profitability if such subsidies are not continued[94] - The company reported a net cash outflow from investment activities of approximately CNY 1.32 billion, primarily due to significant investments in structured deposits[100] - The company has confirmed that there are no major changes in the integrity status of the company and its controlling shareholders during the reporting period[190] Sustainability and Social Responsibility - The company emphasizes its commitment to sustainability and social responsibility initiatives, with a budget of 10 million RMB for community projects[1] - The company has established an environmental management system and implemented measures for waste disposal and pollution management[128] - The company promotes energy conservation and waste reduction initiatives, including a paperless office policy and reduced plastic usage[130] - The company has taken steps to ensure compliance with commitments related to shareholding and management practices, reflecting a focus on corporate governance[135] Corporate Governance and Shareholder Commitments - The actual controller and major shareholders committed to a share lock-up period of 42 months from the date of listing, ensuring stability in shareholding[135] - The company will ensure that any share reduction complies with the relevant laws and regulations, including disclosure requirements[146] - The company has committed to avoiding any form of competition with its subsidiaries and will take effective measures to prevent such activities if listed on domestic stock exchanges[179] - The commitments made by the actual controllers are irrevocable and will remain effective throughout their tenure[182]

Financial Performance - The company's operating revenue for Q1 2022 was ¥72,706,319.65, representing a year-on-year increase of 33.88%[4] - The net profit attributable to shareholders was ¥13,921,971.48, reflecting a year-on-year growth of 17.64%[4] - Total operating revenue for Q1 2022 was ¥72,706,319.65, an increase of 33.9% compared to ¥54,305,590.46 in Q1 2021[17] - Net profit for Q1 2022 reached ¥13,921,971.48, representing a 17.6% increase from ¥11,834,124.97 in Q1 2021[18] - The company reported a total comprehensive income of ¥13,903,726.09 for Q1 2022, compared to ¥11,834,124.97 in Q1 2021[19] Research and Development - R&D investment totaled ¥11,443,479.93, which is an increase of 36.37% compared to the previous year, indicating enhanced R&D capabilities[4][7] - Research and development expenses in Q1 2022 amounted to ¥11,443,479.93, a significant rise of 36.5% compared to ¥8,391,567.71 in Q1 2021[18] - The proportion of R&D investment to operating revenue was 15.74%, an increase of 0.29 percentage points[5] Cash Flow and Liquidity - The net cash flow from operating activities was -¥20,580,327.50, a significant decrease of 803.37% year-on-year, primarily due to slower customer payment speeds and increased operational expenses[4][7] - The total cash inflow from operating activities for Q1 2022 was ¥50,345,556.32, a decrease of 9.4% compared to ¥55,275,599.11 in Q1 2021[21] - The net cash outflow from operating activities was ¥20,580,327.50, contrasting with a net inflow of ¥2,925,966.01 in the same period last year[21] - The ending balance of cash and cash equivalents was ¥256,106,060.25, a decrease from ¥64,618,665.71 in the same quarter last year[22] - The cash flow from operating activities was negatively impacted by increased payments to employees, which rose to ¥35,398,217.71 from ¥28,191,409.02 in Q1 2021[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,942,015,807.46, a decrease of 1.12% from the end of the previous year[5] - The company's total assets as of Q1 2022 were ¥1,942,015,807.46, slightly down from ¥1,964,057,227.03 in the previous quarter[15] - Total liabilities decreased to ¥153,430,872.61 in Q1 2022 from ¥180,396,846.80 in Q1 2021[15] - The company's equity attributable to shareholders increased to ¥1,788,584,934.85 in Q1 2022, compared to ¥1,783,660,380.23 in Q1 2021[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,277[9] - The company’s major shareholders include various investment funds, with significant holdings in common stock[11] - The report indicates that the company has not received any declarations of related party transactions among shareholders, maintaining transparency[11] Operational Challenges - The company is facing operational challenges due to COVID-19, impacting logistics and client operations, which may affect future performance[12] - The company has implemented measures to mitigate the impact of the pandemic on its operations, ensuring production continuity[12] Earnings Per Share - Basic earnings per share (EPS) decreased by 10.00% to ¥0.18, while diluted EPS remained unchanged at ¥0.18[4] - The basic earnings per share for Q1 2022 was ¥0.18, down from ¥0.20 in Q1 2021[19]

Financial Performance - The company reported a significant increase in revenue for the fiscal year 2021, achieving a total of RMB 500 million, representing a year-over-year growth of 25%[16]. - The company's operating revenue for 2021 was CNY 275.27 million, representing a year-on-year growth of 40.31%[23]. - Net profit attributable to shareholders increased by 36.59% to CNY 60.86 million, while the net profit after deducting non-recurring gains and losses grew by 60.36% to CNY 52.48 million[26]. - The net cash flow from operating activities reached CNY 111.46 million, an increase of 88.58% compared to the previous year[28]. - The company achieved operating revenue of CNY 275.27 million, a year-on-year increase of 40.31%[136]. - The net profit attributable to shareholders reached CNY 60.86 million, up 36.59% year-on-year[136]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 52.48 million, reflecting a growth of 60.36%[136]. - The gross profit margin may fluctuate due to the diverse nature of the company's main business, which includes genetically modified animal models and related technical services[131]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 2.57 CNY per 10 shares, totaling approximately 20,036,622.84 CNY, which represents 32.92% of the net profit attributable to shareholders for 2021[6]. - The total share capital used for the dividend calculation is 77,963,513 shares, with the actual amount to be confirmed on the dividend record date[6]. - The company does not plan to increase capital reserves or issue bonus shares, with remaining undistributed profits carried forward to the next year[6]. Research and Development - The R&D expenditure for 2021 was RMB 150 million, accounting for 30% of total revenue, reflecting the company's commitment to innovation[16]. - The company maintained a research and development investment ratio of 17.42% of operating revenue[24]. - The company is investing in the development of humanized models for drug testing, which is anticipated to improve the accuracy of preclinical studies[16]. - The company has developed over 7,200 standardized models, including 456 humanized gene-modified models for tumor immunotherapy and 133 spontaneous tumor models for targeted therapy[98]. - The company has established a comprehensive animal model evaluation system covering various disease models for both tumor and non-tumor drug efficacy evaluation[111]. - The company is focusing on gene editing technology to reduce costs and improve efficiency in gene modification research[104]. Market Expansion and Strategy - The company plans to expand its market presence in Asia and Europe, targeting a 15% increase in market share by the end of 2022[16]. - Strategic acquisitions are being considered to enhance the company's research capabilities and product offerings, with a budget allocation of RMB 100 million for potential mergers and acquisitions[16]. - The company aims to enhance its model resource library to meet diverse market demands and maintain its competitive advantage domestically[101]. - The company is committed to deepening its domestic market presence while expanding into overseas markets, particularly in Europe and the U.S.[183]. Operational Efficiency - The company reported a gross margin of 60% for 2021, indicating strong operational efficiency and cost management[16]. - The company has successfully established a one-stop service system from gene-modified animal model construction to phenotypic analysis and pharmacological efficacy evaluation[25]. - The company has a mature SPF-level experimental animal production and operation management system, ensuring compliance with international management standards[81]. Risks and Compliance - The company has detailed the risks it may face in its production and operation processes in the report[4]. - The company faces risks related to the rapid evolution of gene editing technologies, particularly if the current CRISPR/Cas technology is replaced without timely adaptation[118]. - The company must ensure compliance with strict regulations regarding the management of experimental animals to avoid potential penalties[126]. Human Resources - The company emphasizes the importance of talent development, with 89.47% of R&D personnel holding a bachelor's degree or higher[45]. - The company has a research and development team of 76 people, accounting for 14.93% of total employees, with an average salary of CNY 21.81 million[106]. - A talent cultivation and recruitment system is being established to attract high-quality professionals in various fields, enhancing the overall competency of the team[193]. Customer Relationships and Sales - The company has established strong relationships with over 600 research clients and more than 400 industrial clients, enhancing customer stickiness and resource advantages[116]. - The sales and marketing teams are collaborating to enhance customer satisfaction and loyalty by improving service quality and expanding customer acquisition channels, particularly targeting CROs and innovative pharmaceutical companies[189]. - The company is enhancing its customer relationship management by establishing independent sales teams for different customer segments and creating customer profiles to better meet their research needs[189]. Corporate Governance - The company is committed to continuous improvement in corporate governance to protect shareholder rights and ensure effective decision-making processes[195]. - The company held one shareholders' meeting during the reporting period, which complied with legal regulations and had valid attendance and voting procedures[198].